Sloning Further Strengthens its Intellectual Property with new U.S. Patent
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Sloning, a supplier of synthetic biology tools was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology - Slonomics® - allows researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.
Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position.
The absence of functional bias and the ability to select and control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.
“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.
Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position.
The absence of functional bias and the ability to select and control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.
“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.
